drugset / Trial / NCT07628855
A Prospective, Single-arm, Phase II Clinical Trial of Becotatug Vedotin for Injection Combined With Pucotenlimab Injection as a First-line Treatment for Platinum-intolerant Advanced Head and Neck Squamous Cell Carcinoma
Phase 2
Not yet recruiting
30 enrolled
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Affiliated Cancer Hospital of Shantou University Medical College · collabThe University of Hong Kong-Shenzhen Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a randomized, open-label, multi-center phase II trial evaluating the efficacy and safety of the becotatug vedotin in combination with pucotenlimab regimen in patients with advanced head and neck squamous cell carcinoma who are intolerant to platinum-based therapy.
Timeline
- Start
- 2026-05-14
- Primary completion
- 2028-08-30
- Completion
- 2028-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Becotatug Vedotin | Monoclonal antibody | — | — |
| Subject | Pucotenlimab | Monoclonal antibody | — | — |